In conclusion, our study demonstrated that the addition of bevacizumab or ramucirumab to an EGFR‐TKI as a front‐line treatment provided similar PFS and OS, while ramucirumab user had significantly high‐grade hypertension. This evidence concerns the gene EGFR and Hypertension.